We are using cookies

We use cookies to help us improve this website. By continuing to use this site we assume you are giving us consent to use cookies. Find out more in our cookie policy. Close


Webcast recordings from ESC Heart Failure 2018 congress on Monday, May 28th



  • If you have registered to the webcasts before: Login with the login and password you received while registering.
  • If you have not registered before: please register first and then login.


The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data has been collected on the effects of cardiac glycosides, cathecolamines, and phosphodiesthrase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel opener levosimendan has been proposed as a safer inodilator. This series of tutorials focus on how to use safely and effectively levosimendan in acute and advanced heart failure.

Event 1

Login »Register »

11:15–12:15 (CEST) Levosimendan and renal function: how to avoid kidney dysfunction in AHF?

11:15 Cardio-renal syndrome
K. Karason (Sweden)

11:35 Therapeutic options
F. Fedele (Italy)

11:55 Clinical practice
F. Gustafsson (Denmark)

Event 2

Login »Register »

13:15–14:15 (CEST) Levosimendan in HFrEF: what to use, on whom, when and how?

13:15 What is available?
Z. Papp (Hungary)

13:35 Therapeutic needs
V-P. Harjola (Finland)

13:55 Clinical practice
J. T. Parissis (Greece)

Event 3

Login »Register »

15:15–16:15 (CEST) Repetitive use of levosimendan in advanced heart failure

15:15 Scientific evidence in the literature
C. Tschöpe (Germany)

15:35 Patient characteristics
G. Pölzl (Austria)

15:55 Clinical practice and new data
F. Oliva (Italy)